Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Moura (Coronado (S Mamede e S Romão), Portugal), C. Costa (Coronado (S Mamede e S Romão), Portugal), B. Igreja (Coronado (S Mamede e S Romão), Portugal), N. Pires (Coronado (S Mamede e S Romão), Portugal), V. Batalha (Coronado (S Mamede e S Romão), Portugal), M. Bonifacio (Coronado (S Mamede e S Romão), Portugal), P. Soares-Da-Silva (Porto, Portugal). Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension. 3560

Member's Comments

No comment yet.

Related content which might interest you: Reversibility of the monocrotaline pulmonary hypertension rat model Source: Eur Respir J 2013; 42: 553-556 Year: 2013 Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways Source: Eur Respir J 2013; 41: 1116-1125 Year: 2013 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 The effect of Monoamine oxidase A inhibition on experimentally induced pulmonary arterial hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Effects of iptkalim hydrochloride on endothelin-1-induced pulmonary hypertension in rats Source: Eur Respir J 2005; 26: Suppl. 49, 291s Year: 2005 Effect of dexfenfluramine on the development of pulmonary hypertension in mice over-expressing the serotonin transporter Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Overexpression of serotonin receptor 1B (5HT-1B) responsible for overflow induced experimental pulmonary arterial hypertension development Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation Year: 2003 Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Effects of the NO donor molsidomine on prostacyclin synthase gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001